03-12-2018
Artur / iStockphoto.com
AbbVie has granted Pfizer a non-exclusive global licence to its Humira (adalimumab) IP, as announced on Friday, November 30.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Humira, Pfizer, adalimumab, licensing agreement, royalties, arthritis, biosimilar, generic competition, marketing authorisation
Allele drops COVID-19 protein suit against Pfizer, BioNTech
06-01-2022
Pfizer drops Xeljanz patent suits
20-04-2021
Clean sweep for AbbVie in Humira litigation
15-05-2019
Abbvie faces multiple Humira antitrust suits
04-04-2019
Pfizer inks licensing deal with Seattle biotech firm
18-12-2018
NHS to save £300m in biosimilar adalimumab deals
29-11-2018
AbbVie and Momenta announce Humira patent licence agreement
08-11-2018
